European Journal of Medical Genetics · 2022 · 33 citations · 40 references
MedicinePharmacotherapySurgeryGood Clinical PracticeHemostasisVascular SurgeryArteriovenous Malformation SurgeryThrombosisVascular Lesion TreatmentVascular PathologyCapillary TelangiectasiaHepatic Arteriovenous MalformationsHereditary Hemorrhagic TelangiectasiaInterventional GuidanceMultidisciplinary Vascular CareVascular InvolvementVascular Malformation Treatment
Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT prevalence is estimated at 1/6000, i.e. around 85,000 European citizens, and is served by the European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN). HHT treatments depend on clinical manifestations, and span multiple different medical, surgical and interventional disciplines. Separate to local treatments in the nose, in severe settings, intravenous bevacizumab has been proposed as treatment option, and the purpose of the current article is to assess the use of intravenous bevacizumab in patients with HHT in 2022 according to available data.
40
Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor
Laurent David, Christine Mallet, Michelle Kéramidas et al. · Circulation Research · 2008 · 411 citations · Full text
Ian Roberts, Haleema Shakur‐Still, Adefemi Afolabi et al. · The Lancet · 2020 · 389 citations · Full text